Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.63 | N/A | -4.26% |
management commentary, guidance changes, and full analysis available with Pro.
| -4.26% |
Tone: Defensive
Management expressed concern over recent performance metrics. They reiterated their commitment to navigating market challenges.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term growth despite short-term hurdles.
Bristol Myers Squibb's earnings report indicates a slight miss on EPS expectations, contributing to a notable stock decline of 5.5%. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. The defensive tone from management suggests they are aware of the challenges ahead and are focusing on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BROWN & BROWN INC
Jan 23, 2017